Modified PNA-PCR method

References

• Shi C, Hong SM, Lim P, Kamiyama H, Khan M, Anders RA, et al. KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: Implications for the human pancreatic cancer cell of origin. Mol Cancer Res 2009; 7:230 - 6; http://dx.doi.org/10.1158/1541-7786.MCR-08-0206; PMID: 19208745
   PubMed Web of Science ®Google Scholar
• Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28:466 - 74; http://dx.doi.org/10.1200/JCO.2009.23.3452; PMID: 20008640
   PubMed Web of Science ®Google Scholar
• Brink M, de Goeij A, Weijenberg MP, Roemen G, Lentjes M, Pachen MMM, et al. K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis 2003; 24:703 - 10; http://dx.doi.org/10.1093/carcin/bgg009; PMID: 12727799
   PubMed Web of Science ®Google Scholar
• Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008; 9:962 - 72; http://dx.doi.org/10.1016/S1470-2045(08)70206-7; PMID: 18804418
   PubMed Web of Science ®Google Scholar
• Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:1757 - 65; http://dx.doi.org/10.1056/NEJMoa0804385; PMID: 18946061
   PubMed Web of Science ®Google Scholar
• Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:1626 - 34; http://dx.doi.org/10.1200/JCO.2007.14.7116; PMID: 18316791
   PubMed Web of Science ®Google Scholar
• Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, et al. American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27:2091 - 6; http://dx.doi.org/10.1200/JCO.2009.21.9170; PMID: 19188670
   PubMed Web of Science ®Google Scholar
• De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu DS, Siena S, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010; 304:1812 - 20; http://dx.doi.org/10.1001/jama.2010.1535; PMID: 20978259
   PubMed Web of Science ®Google Scholar
• Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarker in cancer patients. Nat Rev Cancer 2011; 11:426 - 37; http://dx.doi.org/10.1038/nrc3066; PMID: 21562580
   PubMed Web of Science ®Google Scholar
• Schwarzenbach H, Alix-Panabières C, Müller I, Letang N, Vendrell JP, Rebillard X, et al. Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res 2009; 15:1032 - 8; http://dx.doi.org/10.1158/1078-0432.CCR-08-1910; PMID: 19188176
   PubMed Web of Science ®Google Scholar
• Schwarzenbach H, Felix KHC, Isbarn H, Huland H, Pantel K. Genomic profling of cell-free DNA in blood and bone marrow of prostate cancer patients. J Cancer Res Clin Oncol 2011; 137:811 - 9; http://dx.doi.org/10.1007/s00432-010-0941-5; PMID: 20683729
   PubMed Web of Science ®Google Scholar
• Bai H, Mao L, Wang HS, Zhao J, Yang L, An TT, et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol 2009; 27:2653 - 9; http://dx.doi.org/10.1200/JCO.2008.17.3930; PMID: 19414683
   PubMed Web of Science ®Google Scholar
• Wang S, An T, Wang J, Zhao J, Wang Z, Zhuo M, et al. Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer. Clin Cancer Res 2010; 16:1324 - 30; http://dx.doi.org/10.1158/1078-0432.CCR-09-2672; PMID: 20145159
   PubMed Web of Science ®Google Scholar
• Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361:958 - 67; http://dx.doi.org/10.1056/NEJMoa0904554; PMID: 19692684
   PubMed Web of Science ®Google Scholar
• Dobrzycka B, Terlikowski SJ, Mazurek A, Kowalczuk O, Niklinska W, Chyczewski L, et al. Circulating free DNA, p53 antibody and mutations of KRAS gene in endometrial cancer. Int J Cancer 2010; 127:612 - 21; http://dx.doi.org/10.1002/ijc.25077; PMID: 19960433
   PubMed Web of Science ®Google Scholar
• Ryan BM, Lefort F, McManus R, Daly J, Keeling PWN, Weir DG, et al. A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up. Gut 2003; 52:101 - 8; http://dx.doi.org/10.1136/gut.52.1.101; PMID: 12477769
   PubMed Web of Science ®Google Scholar
• Luo JD, Chan EC, Shih CL, Chen TL, Liang Y, Hwang TL, et al. Detection of rare mutant K-ras DNA in a single-tube reaction using peptide nucleic acid as both PCR clamp and sensor probe. Nucleic Acids Res 2006; 34:e12; http://dx.doi.org/10.1093/nar/gnj008; PMID: 16432256
   PubMedGoogle Scholar
• Däbritz J, Hänfler J, Preston R, Stieler J, Oettle H. Detection of Ki-ras mutations in tissue and plasma samples of patients with pancreatic cancer using PNA-mediated PCR clamping and hybridisation probes. Br J Cancer 2005; 92:405 - 12; http://dx.doi.org/10.1038/sj.bjc.6602319; PMID: 15655549
   PubMed Web of Science ®Google Scholar
• Thiede C. Bayerd rffer E, Blasczyk R, Wittig B, Neubauer A. Simple and sensitive detection of mutations in the ras proto-oncogenes using PNA-mediated PCR clamping. Nucleic Acids Res 1996; 24:983; http://dx.doi.org/10.1093/nar/24.5.983; PMID: 8600471
   PubMed Web of Science ®Google Scholar
• Ørum H, Nielsen PE, Egholm M, Berg RH, Buchardt O, Stanley C. Single base pair mutation analysis by PNA directed PCR clamping. Nucleic Acids Res 1993; 21:5332; http://dx.doi.org/10.1093/nar/21.23.5332; PMID: 8265345
   PubMed Web of Science ®Google Scholar
• Ogino S, Kawasaki T, Brahmandam M, Yan LY, Cantor M, Namgyal C, et al. Sensitive Sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn 2005; 7:413 - 21; http://dx.doi.org/10.1016/S1525-1578(10)60571-5; PMID: 16049314
   PubMed Web of Science ®Google Scholar
• Gharizadeh B, Herman ZS, Eason RG, Jejelowo O, Pourmand N. Large-scale pyrosequencing of synthetic DNA: A comparison with results from Sanger dideoxy sequencing. Electrophoresis 2006; 27:3042 - 7; http://dx.doi.org/10.1002/elps.200500834; PMID: 16800029
   PubMed Web of Science ®Google Scholar
• Luthra R, Zuo Z. COLD-PCR finds hot application in mutation analysis. Clin Chem 2009; 55:2077; http://dx.doi.org/10.1373/clinchem.2009.136143; PMID: 19833831
   PubMed Web of Science ®Google Scholar
• Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008; 14:985 - 90; http://dx.doi.org/10.1038/nm.1789; PMID: 18670422
   PubMed Web of Science ®Google Scholar
• Yung TKF, Chan KCA, Mok TSK, Tong J, To KF, Lo YMD. single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer Patients. Clin Cancer Res 2009; 15:2076 - 84; http://dx.doi.org/10.1158/1078-0432.CCR-08-2622; PMID: 19276259
   PubMed Web of Science ®Google Scholar
• Monaco SE, Nikiforova MN, Cieply K, Teot LA, Khalbuss WE, Dacic S. A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases. Hum Pathol 2010; 41:94 - 102; http://dx.doi.org/10.1016/j.humpath.2009.06.019; PMID: 19740513
   PubMed Web of Science ®Google Scholar
• Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010; 16:790 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-09-2446; PMID: 20103678
   PubMed Web of Science ®Google Scholar
• Kalikaki A, Koutsopoulos A, Trypaki M, Souglakos J, Stathopoulos E, Georgoulias V, et al. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer 2008; 99:923 - 9; http://dx.doi.org/10.1038/sj.bjc.6604629; PMID: 19238633
   PubMed Web of Science ®Google Scholar
• Gilje B, Heikkila R, Oltedal S, Tjensvoll K, Nordgard O. High-fidelity DNA polymerase enhances the sensitivity of a peptide nucleic acid clamp PCR assay for K-ras mutations. J Mol Diagn 2008; 10:325 - 31; http://dx.doi.org/10.2353/jmoldx.2008.070183; PMID: 18556764
   PubMed Web of Science ®Google Scholar